0001209191-17-048408.txt : 20170810
0001209191-17-048408.hdr.sgml : 20170810
20170810160610
ACCESSION NUMBER: 0001209191-17-048408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170809
FILED AS OF DATE: 20170810
DATE AS OF CHANGE: 20170810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daly David
CENTRAL INDEX KEY: 0001320267
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36086
FILM NUMBER: 171021503
MAIL ADDRESS:
STREET 1: 33171 PASEO CERVEZA
CITY: SAN JUAN CAPISTRANO
STATE: CA
ZIP: 92675
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foundation Medicine, Inc.
CENTRAL INDEX KEY: 0001488613
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 271316416
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-418-2200
MAIL ADDRESS:
STREET 1: 150 SECOND STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-09
0
0001488613
Foundation Medicine, Inc.
FMI
0001320267
Daly David
C/O FOUNDATION MEDICINE, INC.
150 SECOND STREET
CAMBRIDGE
MA
02141
0
1
0
0
Chief Commercial Officer
Common Stock
2017-08-09
4
M
0
46872
22.24
A
163133
D
Common Stock
2017-08-09
4
S
0
46872
39.50
D
116261
D
Stock Option (right to buy)
22.24
2017-08-09
4
M
0
46872
0.00
D
2024-12-05
Common Stock
46872
28128
D
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.05 to $40.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
This option was granted on December 5, 2014 and is exercisable (i) with respect to 25% of the shares subject to the options, on November 30, 2015, and (ii) with respect to 6.25% of the shares subject to the option, on each subsequent three month period beginning February 28, 2016 until fully vested.
/s/ Robert W. Hesslein, as Attorney-in-Fact for David Daly
2017-08-10